Research programme: antifibrotic and antiinflammatory therapeutics - Anteros Pharmaceuticals
Latest Information Update: 28 Mar 2024
At a glance
- Originator Yale University
- Developer Anteros Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibrosis; Inflammation